Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Traditional Chinese Medicine Grows As Target For New Drug Opportunities

This article was originally published in The Tan Sheet

Executive Summary

Nestle Health and Hutchison China MediTech’s JV has an ongoing phase III trial hoping to validate traditional Chinese medicine for Western health care systems. Reports of TCM contamination at China-based firms represent a market-incursion opportunity for Western firms with established supply chains.

You may also be interested in...



Nestle China JV Backs Nutritional And Rx Botanical Development

Nestle Health Science and Chi-Med’s joint venture Nutrition Science Partners creates an opportunity to develop and commercialize scientifically validated botanical nutritionals and drugs, based in part on Chi-Med’s traditional Chinese medicine library of 1,200 plants and 50,000 extracts.

China's Tasly Focuses On Plant-based Medicines To Gain Entry To U.S.Market

SHANGHAI - After positive Phase II results in the United States last year, Chinese pharmaceutical company Tasly Group has announced an investment of $40 million to build a manufacturing facility and training center in Maryland to help introduce its Compound Danshen Dripping Pills (CDDP) to the American market

Sanofi Acquires BMP Sunstone To Expand Chinese Consumer Health Portfolio

Sanofi-Aventis gains a leadership position in China's OTC cough/cold market with its $520.6 million acquisition of BMP Sunstone, the latest in the global pharma's parade of consumer health buys.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS106581

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel